Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability in and could produce interindividual differences in clinical outcomes. A syst...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-04, Vol.14 (4), p.878
Main Authors: Megías-Vericat, Juan Eduardo, Martínez-Cuadrón, David, Solana-Altabella, Antonio, Poveda, José Luis, Montesinos, Pau
Format: Article
Language:English
Subjects:
ABCB1
ABCC1
ABCG2
Bone marrow
Breast cancer
Cancer therapies
Chemotherapy
Gene expression
Haplotypes
Leukemia
Pediatrics
Polymorphism
SLC29A1
SLCO1B1
Systematic Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antineoplastic uptake by blast cells in acute myeloid leukemia (AML) could be influenced by influx and efflux transporters, especially solute carriers (SLCs) and ATP-binding cassette family (ABC) pumps. Genetic variability in and could produce interindividual differences in clinical outcomes. A systematic review was performed to evaluate the influence of and polymorphisms and their combinations on efficacy and safety in AML cohorts. Anthracycline intake was especially influenced by polymorphisms, associated with lower hepatic uptake, showing higher survival rates and toxicity in AML studies. The variant alleles of were related to anthracycline intracellular accumulation, increasing complete remission, survival and toxicity. Similar findings have been suggested with and polymorphisms. Polymorphisms of , responsible for cytarabine uptake, demonstrated significant associations with survival and response in Asian populations. Promising results were observed with and combinations regarding anthracycline toxicities. Knowledge of the role of transporter pharmacogenetics could explain the differences observed in drug disposition in the blast. Further studies including novel targeted therapies should be performed to determine the influence of genetic variability to individualize chemotherapy schemes.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14040878